Related Experiment Video
Updated: Apr 24, 2026
06:43
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
137
GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)
Andrés Poveda1, Xavier García del Muro, Jose Antonio López-Guerrero
1Instituto Valenciano de Oncología, Calle del Profesor Beltrán Bàguena, 8, 46009, Valencia, Spain, apoveda@fivo.org.
Cancer Chemotherapy and Pharmacology
|September 7, 2014
Summary
Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma. Understanding GIST mutations is crucial for diagnosis, risk classification, and developing targeted therapies for this complex disease.
Area of Science:
- Oncology
- Gastroenterology
- Pathology
Background:
- Gastrointestinal stromal tumors (GIST) represent the most frequent mesenchymal soft tissue sarcoma originating in the gastrointestinal tract.
- Accurate diagnosis and molecular characterization of GIST mutations are paramount for patient management.
- Most GIST cases (95%) are KIT-positive and frequently exhibit activating mutations in KIT or platelet-derived growth factor receptor α (PDGFRA).
Purpose of the Study:
- To provide an updated guideline for the diagnosis and treatment of GIST.
- To incorporate recent advancements in understanding GIST molecular pathology and targeted therapies.
- To address controversies in the adjuvant setting and evolving treatment strategies for advanced GIST.
Main Methods:
- Review of current literature and recent clinical trial data.
- Expert consensus and collaborative effort from the Spanish Group for Sarcoma Research.
- Integration of pathological and molecular diagnostic tools.
Main Results:
- Deep molecular understanding enables precise risk stratification, impacting prognosis and guiding targeted therapy selection.
- Recent trials in advanced GIST have refined treatment protocols.
- Ongoing controversies in the adjuvant setting necessitate updated clinical practice guidelines.
Conclusions:
- Updated GIST guidelines are essential for clinicians managing this complex malignancy.
- Molecular classification is key for personalized treatment strategies and predicting drug response.
- This guideline serves as a practical resource for multidisciplinary teams involved in GIST care.
